MedPath

A clinical trial of autologous stem cell transplantation for severe systemic sclerosis

Phase 2
Conditions
systemic sclerosis
Registration Number
JPRN-jRCTc071190041
Lead Sponsor
Akashi Koichi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
12
Inclusion Criteria

A patient aged 16 to 64 who were diagnosed as systemic sclerosis with performance status (ECOG) 0 to 2. a) Within 4 years after onset and modified Rodnan total skin thickness score (mRSS) is 15 or more , and applicable to one of the following organ complication 1) Pulmonary complications: interstitial pneumonia diagnosed by chest X-ray examination or chest CT, and %FVC or %DLCO is less than 80%. 2) Renal complications: systolic blood pressure is 160 mmHg or more or diastolic blood pressure is 110 mmHg or more, urinalysis abnormality (urine protein, urine occult blood, urinary sediment ), microangiopathic hemolytic anemia, or elevated serum creatinine. 3) cardiac complications: reversible heart failure, or arrhythmia (supraventricular, ventricular, AV block), or pericardial effusion b) 1) Involvement of sclerosis to the trunk within 2 years after onset, mRSS is 20 or more, and 2) ESR is 25 mm/1h or more and/or Hb is 11 g/dL or less.

Exclusion Criteria

A patient with one of the following severe organ complication, a) Heart: uncontrollable arrhythmia, uncontrollable heart failure, LVEF is less than 50% in cardiac ultrasound examination, moderate or more pulmonary hypertension (mean pulmonary artery pressure is 40 mmHg or more) b) Lung: PaO2 is less than 60 mmHg at room air, %VC is less than 50%. %DLCO is less than 20%. c) Kidney: renal glomerular filtration rate is less than 40 ml/min, serum creatinine is 2 mg/dl or more. d) Uncontrolled malignant neoplasm. e) Uncontrollable infection. f) Cyclophosphamide is used more than 10 g in total.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath